By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885



Company News
Janssen-Cilag International NV (JNJ) Submits European Extension Marketing Authorisation Application For Paliperidone Palmitate Once-Every-Three-Months Formulation 8/21/2015 9:29:19 AM
Janssen-Cilag International NV (JNJ) Release: STELARA Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe 5/22/2015 6:28:47 AM
European Commission (EC) Approves Janssen-Cilag International NV (JNJ)'s Rezolsta 11/25/2014 5:48:11 AM
Janssen-Cilag International NV (JNJ) Release: CHMP Announces Positive Opinion For REZOLSTA™, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat 9/29/2014 8:49:54 AM
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014 11:23:27 AM
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014 11:21:55 AM
Janssen-Cilag International NV (JNJ) Release: Post-Hoc Analysis Shows Treatment With INVOKANA® (Canagliflozin) Reduces Both Hba1c And Body Weight In Most Patients With Type 2 Diabetes Mellitus On A Background Of Metformin 9/17/2014 11:20:32 AM
Janssen-Cilag International NV (JNJ) Supports The TeamBG Cycle Tour Raising Awareness Of Diabetes 9/10/2014 11:59:23 AM
Janssen-Cilag International NV (JNJ) Submits EU Marketing Application For VELCADE® (Bortezomib) In Mantle Cell Lymphoma 6/27/2014 10:24:45 AM
Janssen-Cilag International NV (JNJ) Release: OLYSIO™ (Simeprevir) Receives Marketing Authorization In The European Union For The Treatment Of Adults With Hepatitis C Genotype 1 And 4 Infection 5/16/2014 8:58:39 AM